MetaCap

Cigna Group (CI) vs Quest Diagnostics (DGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Quest Diagnostics (DGX) has outperformed Cigna Group (CI) over the past year, gaining 35.0% versus a loss of 2.6%. Over five years, DGX leads with a +66.7% price change compared with +34.1% for CI. Cigna Group is the larger company by market cap ($71.38 billion vs $28.42 billion), about 2.5 times the size, while Quest Diagnostics is growing revenue faster (+11.8% vs +11.2%).

On valuation, Cigna Group trades at a lower forward P/E (8.1x vs 21.6x for Quest Diagnostics). Cigna Group offers the higher dividend yield (2.28% vs 1.31%). Quest Diagnostics converts more of its revenue into profit, with a net margin of 9.0% versus 2.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CI-2.59%DGX+35.05%
+39%+14%-12%
Nov 21, 20251 yearNov 20, 2026
CI+28.69%DGX+74.00%
+80%+28%-23%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CI versus DGX key metrics
MetricCIDGX
Share price$270.90$258.28
Market cap$71.38B$28.42B
1-day change-0.78%-0.31%
YTD return-1.57%+48.84%
1-year return-2.59%+35.05%
5-year return+34.09%+66.69%
P/E ratio (TTM)11.9425.73
Forward P/E8.1421.55
EPS (TTM)$22.68$10.04
Dividend yield2.28%1.31%
Annual dividend$6.19$3.38
Revenue (latest FY)$274.90B$11.04B
Revenue growth (YoY)+11.24%+11.78%
Net income (latest FY)$5.96B$992.00M
Gross margin21.79%33.21%
Operating margin3.35%14.10%
Net margin2.17%8.99%
52-week high$318.05$263.19
52-week low$257.85$171.18
Distance from 52-week high-14.82%-1.87%
Analyst consensusbuybuy
Avg. price target upside+27.13%-0.39%
Average volume1.66M1.03M
Shares outstanding263.50M110.02M
Employees65,66960,000
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Cigna Group is about 2.5 times larger than Quest Diagnostics by market value ($71.38B vs $28.42B).
  • DGX has outperformed CI by 37.6 percentage points over the past year.
  • Quest Diagnostics trades at a higher earnings multiple (25.7x vs 11.9x trailing P/E).
  • Quest Diagnostics is more profitable, keeping 9.0 cents of every revenue dollar as net income versus 2.2 cents for Cigna Group.

About Cigna Group

CI stock →

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare.

Health Care · Medical Specialities · 65,669 employees

About Quest Diagnostics

DGX stock →

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Health Care · Medical Specialities · 60,000 employees

CI vs DGX FAQ

Which is bigger, Cigna Group or Quest Diagnostics?

Cigna Group (CI) is larger, with a market capitalization of $71.38B compared with $28.42B for Quest Diagnostics (DGX).

Which stock has performed better over the past year, CI or DGX?

DGX returned +35.05% over the past 12 months, compared with -2.59% for CI (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, CI or DGX?

CI has the lower trailing P/E at 11.9, versus 25.7 for DGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Cigna Group or Quest Diagnostics?

Cigna Group has the higher yield at 2.28%, compared with 1.31% for Quest Diagnostics.

Are Cigna Group and Quest Diagnostics in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons